Among these, many inhibit enzymes that have been identified as potential therapeutic targets in lymphomas such as hexokinase 2 (HK2), which catalyzes the first committed step in glycolysis, or mitochondrial dihydroorotate dehydrogenase, which is important for pyrimidine synthesis [96,97]. This evidence concerns the gene HK2 and lymphoma.